ARE: Alexandria Sells $1B 7.25% Subordinated Notes

Alexandria priced $1.0 billion of junior subordinated notes bearing a 7.25% coupon and maturing in 2057. The offering increases Alexandria's subordinated capital base; specifics on covenants, ranking relative to other debt, and planned use of proceeds were not provided in the materials available for this report. The issuance should be considered in the context of Alexandria's 2025 year-end financial position and disclosed risks. Key 2025 disclosures include real estate investments carried at $28.7 billion (including $556.7 million held for sale) and a $2.2 billion real estate impairment recorded in 2025. The 2025 consolidated financial metrics (amounts noted in source materials are expressed in thousands) show total liabilities of $14,925,399 and stockholders' equity of $19,097,648 (which includes approximately $15.5 billion of additional paid-in capital). The company reported a net loss of $(1,216,726) for 2025 and recorded $642,445 gain on real estate sales; interest paid (net of capitalized interest) for 2025 was $204,030. Investors weighing the subordinated note should factor in Alexandria's exposure to: (1) previously disclosed impairment risk tied to rental-rate assumptions, exit cap rates and construction costs; (2) environmental and regulatory liabilities that can affect valuation and liquidity; and (3) macroeconomic and tenant-credit sensitivity in the life science sector. The 2025 10-K also discloses development and redevelopment execution risks and limits on certain transactions arising from covenants in senior notes.

The $1.0 billion subordinated issuance follows other 2026 financing activity disclosed in Alexandria's filings. Notably, on 2026-07-09 Alexandria entered into a $5.0 billion revolving credit facility agreement (previously disclosed) and in February 2026 issued $750 million of 5.25% senior notes due 2036. Those items, together with this subordinated note, change Alexandria's capital structure composition and maturity ladder; the subordinated notes will rank junior to senior indebtedness. Alexandria's stated strategy emphasizes liquidity and leverage management through operating cash flow, dispositions, non-real-estate investment sales, and equity/joint-venture capital. The company also discloses non-real-estate investments (additions of $238.8 million in 2025 with sales/distributions of $169.0 million and a net loss of $56.3 million) as part of its broader capital deployment activities. As a REIT focused on Class A/A+ life science properties and Megacampus development, Alexandria's financing choices are framed by development pre-leasing discipline and covenants that can limit certain corporate transactions.